The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk (NVO) announced that the Food and ... along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular ...

Novo Nordisk Says It Is Gradually Phasing Out Human ... in Diabetes Automated insulin delivery systems not only improved glycemic endpoints but also alleviated disease burden and enhanced quality ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

I’m cautious about Novo Nordisk's stock in the short term due ... and cagrilintide (amylin analog), targeting weight loss and glycemic control. Phase 2 trial was completed in August 2022 ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

Wegovy (semaglutide), a once-weekly GLP-1 agonist, has already overtaken Novo Nordisk's once-daily obesity therapy Saxenda (liraglutide) in terms of the number of physicians prescribing the two drugs.

One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index ... shares of Novo-Nordisk AS (Symbol: NVO) entered ...